ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
– Children’s Oncology Group (COG) to Present Data from Investigator-sponsored Study at 59th American Society of Clinical Oncology (ASCO) Annual Meeting – – Phase 3 Clinical Trial of ADCETRIS Combination Therapy Demonstrated a 59% Reduction in Risk of Disease Progression or Relapse, Second Malignancy or Death vs. Standard of Care – – Data Supported Seagen’s … [Read more…]
